12-06-2022, 09:30 AM
Moderna, Inc. MRNA announced positive data from a phase II/III study, which evaluated its second bivalent COVID-19 vaccine booster candidate mRNA-1273.214, targeting the Omicron variant.
Additionally, in March 2022, the FDA authorized the use of a second booster dose of Moderna and Pfizer/BioNTech vaccines in older individuals (aged 50 years and beyond) as well as in certain immunocompromised individuals, aged 18 years and above.
Shares of Moderna have lost 41.5% in the year so far compared with the industry’s 22.8% decline.
https://www.nasdaq.com/articles/modernas...study-goal
Additionally, in March 2022, the FDA authorized the use of a second booster dose of Moderna and Pfizer/BioNTech vaccines in older individuals (aged 50 years and beyond) as well as in certain immunocompromised individuals, aged 18 years and above.
Shares of Moderna have lost 41.5% in the year so far compared with the industry’s 22.8% decline.
https://www.nasdaq.com/articles/modernas...study-goal